T1	intervention 75 84	Celecoxib
T2	intervention 92 102	Exemestane
T3	outcome-Measure 422 437	change in Ki-67
T4	outcome-Measure 468 504	modulation of circulating biomarkers
T5	intervention-participants 650 652	50
T6	intervention-participants 684 686	50
T7	control 692 699	placebo
T8	control-participants 705 707	25
T9	outcome 868 886	reduction in Ki-67
T10	iv-bin-percent 864 867	10%
T11	iv-bin-percent 955 958	15%
T12	outcome 968 995	reduction in PgR expression
T13	outcome 1088 1110	increased testosterone
T14	outcome 1156 1170	decreased SHBG
T15	outcome 1222 1257	decreased total and HDL cholesterol
T16	outcome 1328 1341	Triglycerides
T17	iv-cont-median 1126 1136	0.21 ng/mL
T18	iv-cont-median 1186 1198	-14.6 nmol/L
T19	iv-cont-median 1261 1270	-10 mg/dL
T20	iv-cont-median 1287 1295	-7 mg/dL
T21	iv-cont-median 1385 1395	-0.5 mg/dL
T22	iv-cont-median 1417 1425	-8 mg/dL
